Disruption of the podocyte–endothelial–VEGF axis results in loss of endothelial fenestrations, endotheliosis, podocytes loss, and subsequent proteinuria.5,8 Pathological findings often include kidney-limited thrombotic microangiopathy (TMA) (Figure 5) in patients treated with VEGF inhibitors and minimal change disease or focal segmental glomerulosclerosis with mTKIs.5,6. Here, VEGFA is linked to thrombotic microangiopathy.